However, anti-VEGF monotherapy is licensed for exudative AMD and so withholding it might be considered unethical, more so as our synthesis of the literature suggests anti-VEGF monotherapy produces outcomes that are far better than observation. This evidence concerns the gene VEGFA and age-related macular degeneration.